Tadalafil Tablets Recalled for Incorrect Product Formulation
Sun Pharmaceutical Industries is recalling Tadalafil 5 mg tablets (Lot # DNC1127A) because an incorrect grade of Crospovidone was used during manufacturing. The product was distributed to one distributor who may have further distributed it nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall involving a formulation defect (incorrect excipient grade). No illnesses or injuries are reported in the source text, and no specific safety outcome is stated. The recall appears to be precautionary in nature, warranting a Moderate severity rating.
Plain-English summary
Sun Pharmaceutical Industries Inc is recalling Tadalafil Tablets, USP 5 mg, 30-count bottles due to incorrect product formulation. An incorrect grade of Crospovidone was used to manufacture the product. This is a Class II recall issued by the FDA.
The affected product includes Lot # DNC1127A with an expiration date of 05/2023, bearing NDC # 16714-075-01. Approximately 73,957 30-count bottles were affected. The product was distributed to one distributor who may have further distributed the product nationwide.
Consumers who have this product should consult their healthcare provider or pharmacist for guidance. Healthcare providers and pharmacists should quarantine the product and return it to the manufacturer.
The recalled product
- Product
- TADALAFIL (TADALAFIL)
- Brand
- TADALAFIL
- Manufacturer
- SUN PHARMACEUTICAL INDUSTRIES INC
- Hazard
- formulation-defect
- incorrect-excipient
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # DNC1127A
- exp. date 05/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · TADALAFIL
- ModerateTadalafil Tablets 20 mg recalled due to manufacturing deviations
FDA (Drugs) · 2023-05-03
- HighTadalafil Tablets Recalled Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-05-03
- ModeratePrescription Tadalafil tablets recalled for manufacturing process deviations
FDA (Drugs) · 2023-04-12
- ModerateTadalafil tablets recalled due to manufacturing process deviations
FDA (Drugs) · 2023-03-08
- HighTadalafil tablets recalled for manufacturing quality control deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27